---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-000640"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2023-01-04T23:59:59+00:00"
generated_at: "2026-06-20T20:09:40.020291+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BrainStorm promotes Dr. Lindborg to Co-CEO; Dr. Kern retires as CMO with separation package

## Summary
- Dr. Stacy Lindborg appointed Co-CEO, base salary $500K, annual bonus 40% of salary, 250K RSU equity grant.
- Dr. Ralph Kern retires as President and CMO effective Jan 20, 2023; receives $250K severance, 150K shares, $125K prorated bonus.
- Unvested equity that would vest within six months accelerates for Dr. Kern upon separation.
- Dr. Kern to join Scientific Advisory Board at $450/hour, up to 10 hours/month, for two-year term.

## SEC filing metadata
- accession: 0001104659-23-000640
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2023-01-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465923000640/0001104659-23-000640-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465923000640/tm231494d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-000640
- JSON: https://secwatch.observer/filing/0001104659-23-000640.json
- Plain text: https://secwatch.observer/filing/0001104659-23-000640.txt

## Key facts
- Executive change
  Dr. Ralph Kern departed as President and Chief Medical Officer at BRAINSTORM CELL THERAPEUTICS INC..
  - Action: separated
  - Role: President and Chief Medical Officer
  source text: Effective as of January 3, 2023, the Kern Separation Amendment terminates the employment agreement previously entered into between the Company and Dr. Kern on February 28, 2017.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923000640/0001104659-23-000640-index.htm
- Executive change
  Dr. Stacy Lindborg was appointed as Co-Chief Executive Officer at BRAINSTORM CELL THERAPEUTICS INC..
  - Action: appointed
  - Role: Co-Chief Executive Officer
  source text: Dr. Lindborg will be appointed to the position of Co-Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923000640/0001104659-23-000640-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.